Paid Clinical Trials in Santa Monica, CA
As of September 2026, 178 paid clinical trials are recruiting in Santa Monica, California. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Santa Monica offers studies at sites including Sarcoma Oncology Center for conditions such as Advanced Solid Tumor, Breast Neoplasms, Non-small Cell Lung Cancer, Breast Cancer. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Santa Monica
Trials by drug in Santa Monica
Filter results
Newly added in Santa Monica
Posted to ClinicalTrials.gov within the last 60 days — these studies are just starting to recruit.
170 clinical trials
A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
FOG-001 in Locally Advanced or Metastatic Solid Tumors
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
Top Research Study Locations in Santa Monica
Researchers run research studies in Santa Monica, CA at 25 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Sarcoma Oncology Center | Leiomyosarcoma, Sarcoma, Solid Tumor | 10 |
| UCLA | Advanced Solid Tumor, Colorectal Neoplasms, Advanced Solid Tumors | 10 |
| UCLA Hematology/Oncology - Santa Monica | Advanced Solid Tumor, Urothelial Carcinoma, 1st Line NSCLC | 9 |
| Source Healthcare | Degenerative Disc Disease, Degenerative Disc Disease (DDD), Disc Degeneration | 7 |
| Sarcoma Oncology Research Center | Advanced Soft Tissue Sarcoma, Advanced Soft-tissue Sarcoma, Advanced Solid Tumors | 6 |
| Saint John's Cancer Institute | Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 | 5 |
| UCLA Santa Monica Medical Center | AMI, Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps, Gastrointestinal Stromal Cancer | 5 |
| Providence Saint John's Health Center | Acral Melanoma, Advanced Solid Tumor, Basal Cell Carcinoma | 4 |
| Citruslabs | GLP-1, Gastrointestinal Microbiome, Metabolism Disorder | 3 |
| UCLA Medical Center, Santa Monica | Pain, Postoperative, Acute Pulmonary Embolism, Cerebral Palsy | 3 |
| Oruka Therapeutics Investigative Site | Plaque Psoriasis | 2 |
| Pacific Heart Institute | Cardiovascular Diseases, Heart Failure - NYHA II - IV, Hypertension | 2 |
| Providence Saint John's Cancer Institute | Intermediate Risk Non-Muscle Invasive Bladder Cancer, Low-grade Upper Tract Urothelial Carcinoma | 2 |
| Psychedelic Science Institute | Depression, Depression - Major Depressive Disorder, Depression Disorder | 2 |
| Saint John's Health Center - John Wayne Cancer Institute (JWCI) | Advanced Melanoma, Breast Neoplasms | 2 |
| UCLA Health - Santa Monica Cancer Care | Advanced Lung Carcinoma, Extra-Pancreatic Neuroendocrine Tumor (epNET), KRAS G12C | 2 |
| UCLA Hematology/Oncology - Parkside | Breast Neoplasms, Neoplasm Metastasis | 2 |
| UCLA Hematology/Oncology- Santa Monica | Advanced/Metastatic Urothelial Cancer, Cancer of the Prostate, Hormone Sensitive Prostate Cancer | 2 |
| UCLA Medical Center | CRC, Cancer, Cancer Weight Loss | 2 |
| UCLA Santa Monica Hematology Oncology | Solid Tumor, Colorectal Cancer, Non-Small-Cell Lung Cancer | 2 |
| University of California Los Angeles | Extrapulmonary Neuroendocrine Cancer (epNEC), Non-small Cell Lung Cancer | 2 |
| University of California Los Angeles (UCLA) - Cancer Care - Santa Monica | Lymphoma | 2 |
| University of California, Los Angeles | Advanced Solid Tumor, Gastric Adenocarcinoma, Gastric Cancer | 2 |
| University of California, Los Angeles (UCLA) | Breast Neoplasms, Colorectal Cancer, Colorectal Neoplasms | 2 |
| Galderma Investigational | Prurigo Nodularis, Atopic Dermatitis | 2 |
Active & Upcoming Studies in Santa Monica (2026)
Recruiting trials in Santa Monica grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (93 active studies)
- DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy · Phase 3 · Boehringer Ingelheim
- Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors · Phase 2 · Sarcoma Oncology Research Center, LLC
Neurology & pain (8 active studies)
- Clinical Trial Exploring the Outpatient Treatment of Phantom Limb Pain With Ketamine Administration in a Six Month Study With a Minimum Remission Period of 7 Days Between Treatment Session. 25-30 Subjects With an Ongoing History of Significant PLP.--FDA and IRB Approved. · Phase 2, Phase 3 · The Ketamine Research Foundation
- The Effects of a Nutritional Supplement on Sleep Quality · Athletic Greens International
Mental health & behavior (3 active studies)
- RE104 Safety and Efficacy Study in Generalized Anxiety Disorder · Phase 2 · Reunion Neuroscience Inc
- A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder · Phase 3 · Cybin IRL Limited
Cardiovascular (3 active studies)
- Transition to KPL-387 Monotherapy Dosing & Administration Study · Phase 2 · Kiniksa Pharmaceuticals International, plc
- Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure · Boston Scientific Corporation
Diabetes & metabolic (2 active studies)
- Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy · Phase 2 · Endevica Bio
- Starting Technology in At Risk Type 1 Diabetes Study · University of California, Los Angeles
HIV / STI (1 active study)
- Mobile Vehicle-Based Delivery of Lenacapavir Pre-Exposure Prophylaxis in Los Angeles County · University of California, Los Angeles
Common conditions studied in Santa Monica
- Advanced Solid Tumor (8 active studies)
- Breast Neoplasms (7 active studies)
- Non-small Cell Lung Cancer (7 active studies)
- Breast Cancer (6 active studies)
- Ovarian Cancer (6 active studies)
- Solid Tumor (6 active studies)
Leading research sponsors in Santa Monica
- University of California, Los Angeles
- AstraZeneca
- Eli Lilly and Company
- Novartis Pharmaceuticals
- Pfizer
Frequently asked questions
How many paid clinical trials are currently recruiting in Santa Monica?
There are approximately 178 recruiting clinical trials in Santa Monica, California listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Santa Monica pay participants?
Most recruiting trials in Santa Monica compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Santa Monica?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Santa Monica?
The most common conditions under active study in Santa Monica include Advanced Solid Tumor (8), Breast Neoplasms (7), Non-small Cell Lung Cancer (7), Breast Cancer (6), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Santa Monica?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Santa Monica on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Santa Monica?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Santa Monica?
Recruiting research sites in Santa Monica include Sarcoma Oncology Center, UCLA, UCLA Hematology/Oncology - Santa Monica, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Santa Monica right now?
The largest active categories in Santa Monica are Cancer & tumors (93), Neurology & pain (8), Mental health & behavior (3). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.